|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2006-6-14
|
|
pubmed:abstractText |
The aims of this phase I/II study of docetaxel and S-1 were to determine the dose-limiting toxicity (DLT), maximum-tolerated dose (MTD), and recommended dose (RD) in the phase I part and to explore the tumour response, survival and safety in the phase II part. Patients with histologically- or cytologically confirmed unresectable or recurrent gastric cancer were eligible. Treatment consisted of intravenous docetaxel on day 1 (starting dose 50 mg m(-2)) and oral S-1 at a fixed dose of 40 mg m(-2) twice daily on days 1-14, every 4 weeks up to six cycles. Nine patients took part in the phase I portion of the study. The MTD of docetaxel was determined to be 50 mg m(-2), with the DLTs of grade 3 infection associated with grade 3 neutropenia and grade 4 neutropenia during S-1 administration. The RD of docetaxel was 40 mg m(-2) in combination with S-1 40 mg m(-2) b.i.d. The efficacy and safety of this regimen was therefore assessed in 46 patients with at least one measurable lesion. The overall response rate and estimated median overall survival were 46% (95% CI, 31-61%) and 14.0 months (8.3-17.3 months), respectively. The most common grade 3/4 toxicity was neutropenia (67% of patients), which was predictable and manageable. This regimen showed promising activity with moderate toxicities in advanced gastric cancer.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/16773074-10655437,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16773074-10765119,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16773074-10811496,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16773074-10894863,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16773074-12378340,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16773074-12506170,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16773074-12763215,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16773074-12810455,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16773074-15054450,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16773074-15274365,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16773074-15520058,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16773074-15659494,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16773074-15661684,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16773074-15856038,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16773074-15864716,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16773074-16110025,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16773074-16525670,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16773074-16619558,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16773074-7670132,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16773074-7914428,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16773074-8862723,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16773074-9013471,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16773074-9893658
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0007-0920
|
|
pubmed:author |
pubmed-author:AkiyaTT,
pubmed-author:DoiTT,
pubmed-author:EsakiTT,
pubmed-author:HyodoII,
pubmed-author:KatoTT,
pubmed-author:KinjoFF,
pubmed-author:KoizumiWW,
pubmed-author:KomatsuYY,
pubmed-author:MaedaYY,
pubmed-author:MiyataYY,
pubmed-author:MunakataMM,
pubmed-author:NakanoSS,
pubmed-author:NaraharaHH,
pubmed-author:SaitohSS,
pubmed-author:SakataYY,
pubmed-author:ShimamuraTT,
pubmed-author:TakiuchiHH,
pubmed-author:YamaguchiKK
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
19
|
|
pubmed:volume |
94
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1803-8
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:16773074-Adenocarcinoma,
pubmed-meshheading:16773074-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16773074-Dose-Response Relationship, Drug,
pubmed-meshheading:16773074-Drug Combinations,
pubmed-meshheading:16773074-Female,
pubmed-meshheading:16773074-Humans,
pubmed-meshheading:16773074-Male,
pubmed-meshheading:16773074-Maximum Tolerated Dose,
pubmed-meshheading:16773074-Oxonic Acid,
pubmed-meshheading:16773074-Stomach Neoplasms,
pubmed-meshheading:16773074-Survival Analysis,
pubmed-meshheading:16773074-Survival Rate,
pubmed-meshheading:16773074-Taxoids,
pubmed-meshheading:16773074-Tegafur,
pubmed-meshheading:16773074-Treatment Outcome
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer.
|
|
pubmed:affiliation |
Department of Gastroenterology, Saitama Cancer Centre, Ina-machi, Kitaadachi-gun, Japan. k-yamaguchi@cancer-c.pref.saitama.jp
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II,
Clinical Trial, Phase I
|
